Inflammatory modulation of PPAR gamma expression and activity

Nitric oxide (NO) production increases with age in the lupus-prone MRL/lpr mouse, paralleling disease activity. One mechanism for excess NO production in MRL/lpr mice may be a defect in down-regulatory mechanisms of the iNOS pathway. A potential modulator of NO is the nuclear hormone receptor peroxi...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 118(2006), 2-3 vom: 15. Feb., Seite 276-83
1. Verfasser: Crosby, Michelle B (VerfasserIn)
Weitere Verfasser: Zhang, John, Nowling, Tamara M, Svenson, John L, Nicol, Christopher J, Gonzalez, Frank J, Gilkeson, Gary S
Format: Aufsatz
Sprache:English
Veröffentlicht: 2006
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Inflammation Mediators PPAR gamma Nitric Oxide 31C4KY9ESH Nitric Oxide Synthase Type II EC 1.14.13.39 Nos2 protein, mouse
Beschreibung
Zusammenfassung:Nitric oxide (NO) production increases with age in the lupus-prone MRL/lpr mouse, paralleling disease activity. One mechanism for excess NO production in MRL/lpr mice may be a defect in down-regulatory mechanisms of the iNOS pathway. A potential modulator of NO is the nuclear hormone receptor peroxisome proliferation activated receptor gamma (PPARgamma). We demonstrate that renal PPARgamma protein expression was altered as disease progressed in MRL/lpr mice, which paralleled increased iNOS protein expression. Additionally, MRL/lpr-derived primary mesangial cells expressed less PPARgamma than BALB/c mesangial cells and produced more NO in response to LPS and IFNgamma. Furthermore, PPARgamma activity was reduced in mesangial cells following exposure to inflammatory mediators. This activity was restored with the addition of a NOS enzyme inhibitor. These results indicate that the activation of inflammatory pathways may lead to reduced activity and expression of PPARgamma, further exacerbating the disease state
Beschreibung:Date Completed 30.03.2006
Date Revised 21.11.2013
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035